Michael Boyer

50.3k total citations · 9 hit papers
326 papers, 19.7k citations indexed

About

Michael Boyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Boyer has authored 326 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 175 papers in Pulmonary and Respiratory Medicine and 60 papers in Molecular Biology. Recurrent topics in Michael Boyer's work include Lung Cancer Treatments and Mutations (124 papers), Lung Cancer Research Studies (62 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Michael Boyer is often cited by papers focused on Lung Cancer Treatments and Mutations (124 papers), Lung Cancer Research Studies (62 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Michael Boyer collaborates with scholars based in Australia, United States and Canada. Michael Boyer's co-authors include Kevin Skadron, Shuai Che, Jeremy W. Sheaffer, David Tarjan, Jiayuan Meng, Sangha Lee, U. Gatzemeier, Stephen Clarke, James T. Symanowski and Nicholas J. Vogelzang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Michael Boyer

318 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
Rodinia: A benchmark suite for heterogeneous computing

2009 2.2k citations Michael Boyer et al. profile →
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

2000 768 citations Michael Boyer et al. Journal of Clinical Oncology profile →
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

2017 539 citations Nick Pavlakis, Michael Boyer et al. profile →
A performance study of general-purpose applications on graphics processors using CUDA

2008 451 citations Michael Boyer et al. profile →
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

2017 398 citations Luis Paz‐Ares, Kenneth J. O’Byrne et al. Annals of Oncology profile →
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Ji‐Youn Han, Michael Boyer et al. profile →
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michael Boyer

Since Specialization

Citations

This map shows the geographic impact of Michael Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Boyer more than expected).

Fields of papers citing papers by Michael Boyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Boyer. The network helps show where Michael Boyer may publish in the future.

Co-authorship network of co-authors of Michael Boyer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Boyer. A scholar is included among the top collaborators of Michael Boyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Boyer. Michael Boyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study 2025 ·Annals of Oncology ·Martin Wermke, Sally C. M. Lau, (unknown), (unknown), Kelly G. Paulson, (unknown), (unknown), (unknown), (unknown), Michael Boyer, (unknown), Andrew Parkes, (unknown), Anahita Hamidi, (unknown), (unknown)	0
2	Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives 2024 ·International Journal of Molecular Sciences ·Alan Soo Beng Khoo, Michael Boyer, (unknown), (unknown), (unknown), Levon M. Khachigian, (unknown), Eric M. Dowling, (unknown), David C. Shonka, (unknown), (unknown)	4
3	Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial 2024 ·JTO Clinical and Research Reports ·Benjamin Solomon, Ibiayi Dagogo‐Jack, Se-Hoon Lee, Michael Boyer, Suresh S. Ramalingam, Enric Carcereny, Enriqueta Felip, Ji‐Youn Han, Toyoaki Hida, Brett Hughes, Sang‐We Kim, (unknown), (unknown), Tatsuro Okamoto, Xiaoxi Zhang, Jean‐François Martini, Erjian Wang, Steven De Beukelaer, Todd M. Bauer	1
4	Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update 2024 ·Journal of Clinical Oncology ·Afshin Dowlati, Horst-Dieter Hummel, Stéphane Champiat, M.E. Olmedo, Michael Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa L. Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip, Philipp J. Jost, Shirish M. Gadgeel, (unknown), (unknown), Pablo Martínez, Amanda Parkes, Luis Paz‐Ares	22
5	Clinicians’ Evaluation of Lung Cancer Clinical Quality Indicators and Comparative Performance Data in Practice 2023 ·European Journal of Cancer Care ·Bernadette Brown, (unknown), R. J. Simes, Michael Boyer, Venessa Chin, Jane Young	1
6	Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab 2023 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Abhijit Pal, Adnan Nagrial, Jenny Lee, Po Yee Yip, (unknown), Michael Boyer, Steven Kao, Victoria Bray	4
7	An Australian aged care home for people subject to homelessness: health, wellbeing and cost–benefit 2023 ·BMC Geriatrics ·Claire O’Connor, Roslyn G. Poulos, Anurag Sharma, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Steven Faux, Michael Boyer, Jacqueline Close, Leena Gupta, Christopher J. Poulos	5
8	Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma 2023 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Claude Denham, E. Kaukel, Pierre Ruffiè, U. Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti	18
9	Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer 2023 ·Nanomaterials ·(unknown), Thành Vinh Nguyễn, (unknown), Michael Boyer, David C. Shonka, Levon M. Khachigian	3
10	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study breakdown → 2021 ·Journal of Clinical Oncology ·Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, (unknown)	165
11	A Digital Coaching Intervention for Cancer Survivors With Job Loss: Retrospective Study 2021 ·JMIR Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Michael Boyer, (unknown)	6
12	Understanding Immune Tolerance of Cancer: Re‐Purposing Insights from Fetal Allografts and Microbes 2018 ·BioEssays ·(unknown), Prunella Blinman, Wendy A. Cooper, Michael Boyer, Steven Kao, Christopher C. Goodnow	7
13	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma 2017 ·Pathology ·(unknown), Trina Lum, Carsten E. Palme, Bruce Ashford, Sydney Ch’ng, Marie Ranson, Michael Boyer, Jonathan R. Clark, Ruta Gupta	41
14	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations breakdown → 2013 ·Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2461
15	Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. 2010 ·eSpace (Curtin University) ·Byeongsang Oh, Phyllis Butow, Barbara Mullan, Stephen Clarke, Martin Tattersall, Michael Boyer, Philip Beale, Janette L. Vardy, Nick Pavlakis, (unknown)	33
16	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling 2009 ·Cancer Research ·(unknown), Brian Y. Lee, David A. Brown, Mark P. Molloy, Gavin Marx, Nick Pavlakis, Michael Boyer, Martin R. Stockler, Warren Kaplan, Samuel N. Breit, Robert L. Sutherland, Susan M. Henshall, Lisa G. Horvath	86
17	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer 2009 ·American Journal of Clinical Oncology ·Carmel Pezaro, Mark Rosenthal, Howard Gurney, Ian D. Davis, Craig Underhill, Michael Boyer, Dusan Kotasek, Benjamin Solomon, Guy C. Toner	42
18	Diagnosis and treatment of testicular cancer 2001 ·Michael Boyer	1
19	An antigen-specific helper T cell hybridoma produces an antigen-specific suppressor inducer molecule with identical antigenic fine specificity. Implications for the antigen recognition and function of helper and suppressor inducer T cells. 1988 ·The Journal of Immunology ·Hui Zheng, Michael Boyer, Arun Fotedar, Bhagirath Singh, Douglas R. Green	19
20	Technique de dosage du céfotaxime et du desacétyl-céfotaxime dans le sérum par chromatographie liquide haute performance. 1984 ·Michael Boyer, J. Sirot, R Cluzel, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact